ELI LILLY & Co is 746.3x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($1.072 T vs $1.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KALV | LLY |
|---|---|---|
| Market cap | $1.44 B | $1.072 T |
| US-listed rank | #2363 | #10 |
| Revenue (latest FY) | $50.00M | $65.18B |
| Net income (latest FY) | -$183.40M | $20.64B |
| Net margin | -366.8% | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 834 | 989 |
ELI LILLY & Co is 746.3x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($1.072 T vs $1.44 B).
In their latest fiscal years, KalVista Pharmaceuticals, Inc. reported $50.00M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: KalVista Pharmaceuticals, Inc. and ELI LILLY & Co, or browse the full rankings.